Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference

WALTHAM, Mass. – May 15, 2024 – Upstream Bio, Inc., a clinical-stage company focused on the development of verekitug, a potential first-in-class antagonist of the Thymic Stromal Lymphopoietin (TSLP) receptor that may deliver best-in-class efficacy for people with severe asthma and related diseases, today announced an upcoming presentation featuring clinical data from its dose-ranging study […] The post Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference appeared first on Upstream